Rating Change
Canaccord Genuity analysts reiterated a Buy rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) on June 26, 2026.
reiterateNASDAQ:KYMR
Canaccord Genuity Reiterates Buy Rating on Kymera Therapeutics, Inc. (KYMR)
Rating Change Canaccord Genuity analysts reiterated a Buy rating on Kymera Therapeutics, Inc. (NASDAQ:KYMR) on June 26, 2026. Market Context Kymera Therapeutics, Inc.
Market Context
Kymera Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $108.12 with a market capitalization of $6.3B.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Kymera Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Kymera Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 26, 2026 | Canaccord Genuity | Buy | N/A |
| Jun 25, 2026 | BTIG | Buy | N/A |
| May 06, 2026 | Canaccord Genuity | Buy | N/A |
| Mar 03, 2026 | UBS | Buy | N/A |
| Mar 02, 2026 | Citigroup | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View KYMR Stock Page
Frequently Asked Questions
What does a Buy rating mean for KYMR?
A Buy rating from Canaccord Genuity reflects the analyst's outlook on Kymera Therapeutics, Inc. (NASDAQ:KYMR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the KYMR forecast page.